Scaling AAV manufacturing across fixed-bed bioreactors: lessons from Novartis (APAC)

Thursday 09:30 IST / 12:00 AWST / 13:00 KST / 13:00 JST / 14:00 AEST / 16:00 NZST

Sponsor

Scaling AAV manufacturing across fixed-bed bioreactors: lessons from Novartis (APAC)

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

Gain practical insight into how adeno-associated virus (AAV) production can be scaled from development studies to manufacturing-relevant scale while maintaining process representativeness in both titer and product quality. In this webinar, Novartis scientists will share batch-level data illustrating how operating parameters were aligned across development-, intermediate-, and manufacturing-scale fixed-bed bioreactor systems.

The session features Xiang Cui, Senior Manager at Novartis Gene Therapies, who oversees a manufacturing science and technology (MS&T) laboratory supporting GMP production of AAV, and Akash Khorran, Upstream MS&T Engineer, the acting subject matter expert for upstream GMP and lab-scale AAV production. Drawing on their experience supporting gene therapy programs from development through manufacturing scale, they will present real, operational data showing how scale-up and scale-down strategies were evaluated during process development.

Attendees will review comparative results demonstrating consistent trends in cell growth, metabolite profiles, genomic titers, and product impurities across scales. The discussion will also highlight which parameters proved critical for maintaining process performance during scale transfer, and how intermediate-scale systems can help reduce development risk and accelerate decision-making ahead of large-scale production.

Attend this webinar to:

Review batch-level data showing how operating parameters were aligned across development-, intermediate-, and manufacturing-scale fixed-bed bioreactors.
Understand which parameters proved critical for maintaining consistent AAV titer, cell growth, metabolite trends, and impurity profiles during scale transfer.
Learn how intermediate-scale systems can support risk reduction and faster decision-making during process development.
Gain practical guidance on designing scale-down experiments and development studies that remain representative of manufacturing conditions.

Please be advised that the Q&A will not be delivered live. We encourage you to submit your questions, and our speakers will respond by email.

Akash Khorran

Upstream Engineer, Manufacturing Science and Technology at Novartis Gene Therapies

Akash Khorran is an Upstream MS&T Engineer at Novartis Gene Therapies, based in Durham, North Carolina. In this role, he is the acting SME for Upstream GMP and lab-scale production of AAV. Akash has experience supporting gene therapies across the development stage and manufacturing scale. He holds a bachelor’s degree in biology from the University of Florida.

Xiang Cui

Senior Manager, Manufacturing Science and Technology at Novartis Gene Therapies

Xiang Cui is a Senior Manager at Novartis Gene Therapies based in Durham, North Carolina. In this role, he is responsible for overseeing MS&T lab which supports GMP production of AAV. Xiang has experience supporting gene therapies and vaccines across development stage and manufacturing scale. He holds an M.S. degree in bioprocess engineering from North Carolina State University.

Dylan Knutson

Upstream Field Application Specialist at Cytiva

Dylan Knutson is an Upstream Field Application Specialist with extensive hands-on experience supporting viral vector manufacturing workflows. He works closely with customers to implement, and optimize iCELLis™ fixed-bed bioreactor platforms, bridging process development, scale-up, and real-world manufacturing challenges. His focus is on translating upstream science into robust, scalable solutions for gene therapy applications.

In 27 Days

You have registered for this webinar